MedTrace Logo

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2025-12-18

No results posted yet for this study

Summary

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Conditions

  • Vestibular Schwannoma
  • Acoustic Neuroma
  • Neurofibromatosis 2

Interventions

DRUG

Aspirin

Twice daily aspirin

DRUG

Placebo

Twice daily placebo

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Konstantina Stankovic, MD, PhD · Stanford University

  • D. Bradley Welling, MD, PhD · Massachusetts Eye and Ear

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-11
Primary Completion
2026-08-31
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03079999 on ClinicalTrials.gov